COVID-19 vaccine response in people with multiple sclerosis

Tallantyre, Emma ORCID: https://orcid.org/0000-0002-3760-6634, Vickaryous, Nicola, Anderson, Valerie, Asardag, Aliye Nazli, Baker, David, Bestwick, Jonathan, Bramhall, Kath, Chance, Randy, Evangelou, Nikos, George, Katila, Giovannoni, Gavin, Godkin, Andrew ORCID: https://orcid.org/0000-0002-1910-7567, Grant, Leanne, Harding, Katherine E, Hibbert, Aimee, Ingram, Gillian, Jones, Meleri, Kang, Angray S, Loveless, Samantha ORCID: https://orcid.org/0000-0002-5124-4115, Moat, Stuart J, Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909, Schmierer, Klaus, Scurr, Martin ORCID: https://orcid.org/0000-0002-4120-0688, Shah, Sita Navin, Simmons, Jessica, Upcott, Matthew, Willis, Mark ORCID: https://orcid.org/0000-0003-3024-6063, Jolles, Stephen and Dobson, Ruth 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1) , pp. 89-100. 10.1002/ana.26251

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (705kB) | Preview

Abstract

Objective To investigate the effect of disease modifying therapies on immune response to SARS-CoV2 vaccines in people with multiple sclerosis. Methods 473 people with multiple sclerosis provided one or more dried blood spot samples. Information about COVID-19 and vaccine history, medical and drug history were extracted from questionnaires and medical records. Dried blood spots were eluted and tested for antibodies to SARS-CoV2. Antibody titres were partitioned into tertiles with people on no disease modifying therapy as a reference. We calculated the odds ratio of seroconversion (univariate logistic regression) and compared quantitative vaccine response (Kruskal Wallis) following SARS-CoV2 vaccine according to disease modifying therapy. We used regression modelling to explore the effect of vaccine timing, treatment duration, age, vaccine type and lymphocyte count on vaccine response. Results Compared to no disease modifying therapy, the use of anti-CD20 monoclonal antibodies (odds ratio 0.03; 95% confidence interval 0.01-0.06, p<0.001) and fingolimod (odds ratio 0.04; 95% confidence interval 0.01-0.12) were associated with lower seroconversion following SARS-CoV2 vaccine. All other drugs did not differ significantly from the untreated cohort. Both time since last anti-CD20 treatment and total time on treatment were significantly associated with response to vaccination. Vaccine type significantly predicted seroconversion, but not in those on anti-CD20 medications. Preliminary data on cellular T-cell immunity showed 40% of seronegative subjects had measurable anti-SARS-CoV2 T cell responses. Interpretation Some disease modifying therapies convey risk of attenuated serological response to SARS-CoV2 vaccination in people with MS. We provide recommendations for the practical management of this patient group.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Additional Information:	This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License
Publisher:	Wiley
ISSN:	0364-5134
Date of First Compliant Deposit:	20 October 2021
Date of Acceptance:	19 October 2021
Last Modified:	26 Nov 2024 23:50
URI:	https://orca.cardiff.ac.uk/id/eprint/144964

Citation Data

Cited 121 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item